Literature-reported formulation composition
Component: 113-O12B | mol%: Not reported | Role: Ionizable lipid
sales@dcchemicals.com
113-O12B
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Literature-reported formulation composition
Component: Cholesterol | mol%: Not reported | Role: Sterol
Literature-reported formulation composition
Component: DOPC | mol%: Not reported | Role: helper_lipid
Literature-reported formulation composition
Component: DMG-PEG2000 | mol%: Not reported | Role: PEG lipid
Literature-reported formulation composition
Component: Reported total | mol%: Not reported | Role: Source values retained
Reported observation
Literature-reported LN targeting 113-O12B showed higher LN and lower liver expression than ALC-0315 after SC dosing; ALC-0315 liver radiance was about fourfold higher than LN radiance, whereas 113-O12B liver signal was 32% of LN signal. mLuc LNP, 6 h after SC injection Primary article Fig. 1D-E
Reported observation
Literature-reported APC transfection Approximately 27% of dendritic cells and 34% of macrophages were positive after 113-O12B/mCre, both higher than ALC-0315 in the same experiment. Ai14 mice, 48 h after SC mCre Primary article Fig. 1F-G
Reported observation
Literature-reported OVA vaccine protection 113-O12B/mOVA vaccination prevented obvious B16F10-OVA tumor growth and prevented apparent lung metastatic nodules in the reported rechallenge experiment. Two vaccinations; 50 µg active lipid + 5 µg mOVA per dose Primary article Fig. 2
Reported observation
Literature-reported Established B16F10-OVA therapy 113-O12B/mOVA prolonged survival; anti-PD-1 combination increased complete response to 2/5 mice in the reported experiment. Established tumor; vaccine days 5 and 12; anti-PD-1 days 7, 11 and 15 Primary article Fig. 4
Reported observation
Literature-reported Regular B16F10/TRP2 therapy 113-O12B/mTRP2 plus anti-PD-1 achieved a 40% complete-response rate and surviving complete responders showed no metastatic lung nodules on rechallenge. 30 µg active lipid + 3 µg TRP2 mRNA per dose Primary article Fig. 5 and Discussion